Although bipolar disorder affects around 2 per cent of the population, studies suggest that up to 50 per cent of people with ...

Bipolar disorder is characterized by extreme mood swings, with individuals cycling between periods of intense energy and ...

Bipolar disorder disrupts sleep patterns, and sleep challenges worsen bipolar symptoms. Prioritizing better rest can help ...

With bipolar, anxiety and panic attacks seem prevalent. Relief is within reach, with the effective coping strategies of ...

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar ...

Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential ...

R-708-5p is a stress-regulated microRNA and a potential biomarker for the differential diagnosis of human mood disorders.

Alzamend Neuro, Inc. announced plans to start a phase II clinical study of AL001, focusing on its use for patients with bipolar disorder (BD), set to begin in the third quarter of 2025.

People with bipolar disorder who followed a ketogenic diet ... This means it was a small, early-phase study in which all participants followed a ketogenic diet for six to eight weeks.